<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>GLP-1 WHO 2026 Compliance Pack ‚Äì Clinics, Tele-Health, Pharmacies & Compounding Partners</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="description"
        content="Professional 2026 WHO GLP-1 compliance guide for clinics, tele-health platforms, pharmacies and compounding partners ‚Äì documentation templates, supply-chain verification, cold-chain logs and audit red-flag checklists." />
  <meta name="robots" content="index,follow" />
  <meta name="author" content="Skillona.ai" />
  <meta name="last-modified" content="2026-01-01" />
  <link rel="icon" href="/favicon.ico" />
  <link rel="canonical" href="https://skillona.ai/glp1-who-guidance-2026/" />

  <!-- Open Graph -->
  <meta property="og:title" content="GLP-1 WHO 2026 Compliance Pack ‚Äì Clinics, Tele-Health, Pharmacies & Compounding Partners" />
  <meta property="og:description"
        content="Full WHO-aligned GLP-1 compliance framework: prescribing justification, off-label documentation, supply-chain & cold-chain logs, marketing restrictions and audit response templates." />
  <meta property="og:type" content="article" />
  <meta property="og:url" content="https://skillona.ai/glp1-who-guidance-2026/" />
  <meta property="og:site_name" content="Skillona.ai" />
  <meta property="og:image" content="https://skillona.ai/assets/og/glp1-who-guidance-2026.png" />

  <!-- Twitter -->
  <meta name="twitter:card" content="summary_large_image" />
  <meta name="twitter:title" content="GLP-1 WHO 2026 Compliance Pack ‚Äì Professional Guide" />
  <meta name="twitter:description"
        content="Step-by-step WHO 2026 GLP-1 compliance system for clinics, tele-health, pharmacies and compounding labs." />
  <meta name="twitter:image" content="https://skillona.ai/assets/og/glp1-who-guidance-2026.png" />

  <style>
    :root {
      --bg: #050814;
      --bg-elevated: #0b1220;
      --bg-soft: #101827;
      --accent: #38bdf8;
      --accent-soft: rgba(56, 189, 248, 0.12);
      --text: #e5e7eb;
      --muted: #9ca3af;
      --border-subtle: #1f2937;
      --danger: #f97373;
      --success: #4ade80;
      --radius-lg: 18px;
      --radius-xl: 26px;
      --shadow-soft: 0 18px 45px rgba(0, 0, 0, 0.55);
      --max-width: 900px;
    }

    * {
      box-sizing: border-box;
      -webkit-font-smoothing: antialiased;
      text-rendering: optimizeLegibility;
    }

    body {
      margin: 0;
      font-family: system-ui, -apple-system, BlinkMacSystemFont, "SF Pro Text",
        "Segoe UI", sans-serif;
      background: radial-gradient(circle at top, #111827 0, #020617 55%, #000 100%);
      color: var(--text);
      min-height: 100vh;
      display: flex;
      justify-content: center;
    }

    .page {
      width: 100%;
      max-width: var(--max-width);
      padding: 28px 18px 40px;
    }

    @media (min-width: 768px) {
      .page {
        padding: 40px 0 64px;
      }
    }

    .shell {
      background: linear-gradient(145deg, rgba(15, 23, 42, 0.96), rgba(2, 6, 23, 0.98));
      border-radius: 32px;
      padding: 28px 20px 30px;
      box-shadow: var(--shadow-soft);
      border: 1px solid rgba(148, 163, 184, 0.16);
      backdrop-filter: blur(26px);
    }

    @media (min-width: 768px) {
      .shell {
        padding: 32px 36px 38px;
      }
    }

    header {
      display: flex;
      flex-direction: column;
      gap: 12px;
      margin-bottom: 26px;
    }

    .tagline {
      font-size: 13px;
      letter-spacing: 0.16em;
      text-transform: uppercase;
      color: var(--muted);
      display: flex;
      align-items: center;
      gap: 10px;
      flex-wrap: wrap;
    }

    .tagline-pill {
      padding: 4px 10px;
      border-radius: 999px;
      background: rgba(15, 23, 42, 0.9);
      border: 1px solid var(--border-subtle);
      display: inline-flex;
      align-items: center;
      gap: 6px;
    }

    .tag-dot {
      width: 6px;
      height: 6px;
      border-radius: 999px;
      background: var(--accent);
      box-shadow: 0 0 0 4px var(--accent-soft);
    }

    h1 {
      font-size: 26px;
      line-height: 1.15;
      letter-spacing: -0.03em;
      margin: 0;
    }

    @media (min-width: 768px) {
      h1 {
        font-size: 32px;
      }
    }

    .subtitle {
      color: var(--muted);
      font-size: 15px;
      max-width: 640px;
    }

    .meta-row {
      display: flex;
      flex-wrap: wrap;
      gap: 10px;
      margin-top: 6px;
      font-size: 12px;
      color: var(--muted);
    }

    .meta-pill {
      padding: 4px 9px;
      border-radius: 999px;
      border: 1px solid var(--border-subtle);
      background: rgba(15, 23, 42, 0.85);
      display: inline-flex;
      align-items: center;
      gap: 6px;
    }

    .meta-pill strong {
      font-weight: 600;
      color: #e5e7eb;
    }

    main {
      display: grid;
      grid-template-columns: minmax(0, 1.9fr) minmax(0, 1.1fr);
      gap: 18px;
    }

    @media (max-width: 900px) {
      main {
        grid-template-columns: minmax(0, 1fr);
      }
    }

    .article {
      background: radial-gradient(circle at top left, rgba(56, 189, 248, 0.12), transparent 55%),
                  radial-gradient(circle at bottom right, rgba(129, 140, 248, 0.12), transparent 52%),
                  linear-gradient(145deg, #020617, #020617);
      border-radius: var(--radius-xl);
      border: 1px solid rgba(55, 65, 81, 0.9);
      padding: 20px 18px 22px;
      position: relative;
      overflow: hidden;
    }

    @media (min-width: 768px) {
      .article {
        padding: 22px 22px 24px;
      }
    }

    .article::before {
      content: "";
      position: absolute;
      inset: 0;
      background: radial-gradient(circle at top right, rgba(59, 130, 246, 0.18), transparent 60%);
      opacity: 0.7;
      pointer-events: none;
      mix-blend-mode: soft-light;
    }

    .article-inner {
      position: relative;
      z-index: 1;
    }

    .section-label {
      font-size: 11px;
      letter-spacing: 0.16em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 6px;
    }

    .article h2 {
      font-size: 18px;
      margin-top: 20px;
      margin-bottom: 8px;
      letter-spacing: -0.02em;
    }

    .article h3 {
      font-size: 15px;
      margin-top: 16px;
      margin-bottom: 6px;
    }

    .article p {
      font-size: 14px;
      line-height: 1.6;
      color: #d1d5db;
      margin: 6px 0 8px;
    }

    .article ul,
    .article ol {
      margin: 6px 0 10px 0;
      padding-left: 18px;
      font-size: 14px;
      color: #d1d5db;
    }

    .article li {
      margin-bottom: 5px;
    }

    .callout {
      margin: 14px 0 12px;
      padding: 10px 12px;
      border-radius: 14px;
      background: rgba(15, 23, 42, 0.96);
      border: 1px solid rgba(55, 65, 81, 0.95);
      font-size: 13px;
      color: #e5e7eb;
      display: flex;
      gap: 10px;
      align-items: flex-start;
    }

    .callout-icon {
      width: 18px;
      height: 18px;
      border-radius: 999px;
      background: var(--accent-soft);
      border: 1px solid var(--accent);
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 11px;
      color: var(--accent);
      flex-shrink: 0;
      margin-top: 2px;
    }

    .checklist {
      border-radius: 16px;
      border: 1px dashed rgba(75, 85, 99, 0.9);
      padding: 10px 12px;
      margin-top: 10px;
      background: rgba(15, 23, 42, 0.9);
    }

    .checklist h3 {
      margin-top: 0;
      font-size: 14px;
    }

    .checklist ul {
      margin: 4px 0 0;
      padding-left: 18px;
    }

    .checklist li::marker {
      content: "‚úì ";
      color: var(--success);
      font-weight: 600;
    }

    .faq {
      margin-top: 16px;
      border-top: 1px solid rgba(31, 41, 55, 0.9);
      padding-top: 10px;
    }

    .faq-item + .faq-item {
      margin-top: 8px;
    }

    .faq-q {
      font-size: 14px;
      font-weight: 600;
      margin-bottom: 2px;
    }

    .faq-a {
      font-size: 13px;
      color: var(--muted);
    }

    .sidebar {
      display: flex;
      flex-direction: column;
      gap: 14px;
    }

    .sidebar-card {
      background: radial-gradient(circle at top left, rgba(56, 189, 248, 0.18), transparent 55%),
                  linear-gradient(145deg, #020617, #020617);
      border-radius: var(--radius-xl);
      border: 1px solid rgba(55, 65, 81, 0.95);
      padding: 14px 14px 16px;
    }

    .sidebar-card h3 {
      margin: 0 0 8px;
      font-size: 14px;
    }

    .sidebar-card p {
      margin: 0 0 10px;
      font-size: 13px;
      color: var(--muted);
    }

    .badge {
      display: inline-flex;
      align-items: center;
      gap: 6px;
      padding: 3px 8px;
      border-radius: 999px;
      background: rgba(15, 23, 42, 0.9);
      border: 1px solid rgba(55, 65, 81, 0.9);
      font-size: 11px;
      text-transform: uppercase;
      letter-spacing: 0.16em;
      color: var(--muted);
      margin-bottom: 6px;
    }

    .badge span {
      font-size: 8px;
      color: var(--accent);
    }

    .link-list {
      list-style: none;
      padding: 0;
      margin: 0;
      font-size: 13px;
    }

    .link-list li + li {
      margin-top: 4px;
    }

    .link-list a {
      color: #e5e7eb;
      text-decoration: none;
    }

    .link-list a:hover {
      color: var(--accent);
    }

    .ad-slot {
      margin-top: 8px;
      border-radius: 14px;
      border: 1px dashed rgba(75, 85, 99, 0.9);
      padding: 10px 8px;
      font-size: 11px;
      text-align: center;
      color: var(--muted);
      background: rgba(15, 23, 42, 0.92);
    }

    .ad-slot.small {
      padding: 6px 6px;
      font-size: 10px;
    }

    footer {
      margin-top: 26px;
      padding-top: 16px;
      border-top: 1px solid var(--border-subtle);
      font-size: 11px;
      color: var(--muted);
      display: flex;
      flex-wrap: wrap;
      justify-content: space-between;
      gap: 8px;
    }

    footer a {
      color: var(--muted);
      text-decoration: none;
    }

    footer a:hover {
      color: var(--accent);
    }

    .btn-primary {
      display: inline-flex;
      align-items: center;
      justify-content: center;
      gap: 6px;
      margin-top: 8px;
      padding: 9px 14px;
      border-radius: 999px;
      background: linear-gradient(135deg, #0ea5e9, #22c1c3);
      color: #0b1120;
      font-size: 13px;
      font-weight: 600;
      text-decoration: none;
      box-shadow: 0 12px 30px rgba(56, 189, 248, 0.45);
      border: 1px solid rgba(125, 211, 252, 0.9);
      cursor: pointer;
    }

    .btn-primary:hover {
      filter: brightness(1.05);
      box-shadow: 0 16px 38px rgba(56, 189, 248, 0.55);
    }
  </style>
</head>

<body>
  <div class="page">
    <div class="shell">

      <header>
        <div class="tagline">
          <div class="tagline-pill">
            <span class="tag-dot"></span>
            WHO ¬∑ GLP-1 ¬∑ COMPLIANCE
          </div>
          <span>Skillona.ai ¬∑ Operational micro-guides for professionals</span>
        </div>
        <h1>GLP-1 WHO 2026 Compliance Pack ‚Äì Clinics, Tele-Health, Pharmacies & Compounding Partners</h1>
        <p class="subtitle">
          January 2026 WHO GLP-1 Global Risk Advisory introduces new requirements for prescribing, documenting,
          monitoring, advertising and supplying GLP-1 medications worldwide. This page summarises the key changes
          and shows what your organisation must document ‚Äì with a complete ready-to-use compliance pack available.
        </p>
        <div class="meta-row">
          <div class="meta-pill">‚è±Ô∏è <strong>Reading time:</strong>&nbsp;10‚Äì15 min</div>
          <div class="meta-pill">üíä <strong>Scope:</strong>&nbsp;Ozempic ¬∑ Wegovy ¬∑ Mounjaro ¬∑ Zepbound ¬∑ Saxenda</div>
          <div class="meta-pill">üåç <strong>Updated:</strong>&nbsp;January 2026 ¬∑ WHO advisory</div>
        </div>
      </header>

      <main>
        <article class="article">
          <div class="article-inner">

            <div class="section-label">Executive overview</div>
            <h2>1. What changed in the WHO 2026 GLP-1 advisory</h2>
            <p>
              The WHO GLP-1 Global Risk Advisory tightens controls on semaglutide, tirzepatide and related GLP-1
              formulations across four axes: prescribing pathways, documentation, supply-chain integrity and public claims.
              Regulators, insurers and platforms are already aligning their audits with this framework.
            </p>
            <ul>
              <li>Mandatory documentation of medical necessity and eligibility.</li>
              <li>Explicit off-label justification and written informed consent.</li>
              <li>Full supply-chain and cold-chain traceability by batch.</li>
              <li>Advertising and claims restricted to non-promissory language.</li>
              <li>Adverse-event logging and escalation pathways.</li>
            </ul>

            <div class="callout">
              <div class="callout-icon">!</div>
              <div>
                The advisory explicitly references <strong>clinics, tele-health platforms, pharmacies, compounding
                facilities, distributors and independent prescribers</strong>. All need auditable documentation ‚Äì not just
                ‚Äúgood intentions‚Äù.
              </div>
            </div>

            <div class="section-label">Who must comply</div>
            <h2>2. Entities directly impacted by the 2026 WHO GLP-1 framework</h2>
            <p>Regulators will focus on any organisation that prescribes, dispenses, compounds or markets GLP-1 products:</p>
            <ul>
              <li>Metabolic and weight-loss clinics (on-site and tele-health).</li>
              <li>Primary-care and endocrinology practices prescribing GLP-1.</li>
              <li>Retail and hospital pharmacies.</li>
              <li>Compounding pharmacies and outsourcing facilities.</li>
              <li>Cross-border and online distributors.</li>
              <li>Wellness brands and ‚ÄúGLP-1 programs‚Äù using white-label partners.</li>
            </ul>

            <div class="section-label">Core documentation</div>
            <h2>3. Required GLP-1 compliance documentation (high-level checklist)</h2>
            <p>At minimum, your files should include:</p>
            <ul>
              <li>Eligibility &amp; diagnosis verification per patient.</li>
              <li>Prescribing rationale &amp; risk‚Äìbenefit assessment.</li>
              <li>Off-label justification where applicable.</li>
              <li>Written informed consent (label / off-label separated).</li>
              <li>Supply-chain verification and COAs for each batch.</li>
              <li>Continuous cold-chain temperature logs.</li>
              <li>Adverse-event reports and escalation outcomes.</li>
              <li>Compounding partner certifications and test reports.</li>
              <li>Marketing / claims review log for all public materials.</li>
            </ul>

            <div class="checklist">
              <h3>Minimal documentation set (per WHO risk themes)</h3>
              <ul>
                <li>Patient-level: eligibility, rationale, consent, monitoring.</li>
                <li>Product-level: batch IDs, COAs, cold-chain logs.</li>
                <li>Partner-level: supplier licences, accreditations, USP standards.</li>
                <li>Public-facing: advertising and claims review + approval trail.</li>
              </ul>
            </div>

            <div class="section-label">Off-label & informed consent</div>
            <h2>4. Off-label usage requirements (weight-loss & beyond)</h2>
            <p>
              Off-label prescribing remains legal in many jurisdictions, but undocumented off-label GLP-1 use is now a
              top audit trigger. Your records should clearly show:
            </p>
            <ul>
              <li>Clinical rationale for off-label use (e.g. obesity with comorbidities).</li>
              <li>Alternatives discussed and why GLP-1 was selected.</li>
              <li>Documented patient expectations and limitations of evidence.</li>
              <li>Signed off-label informed consent, stored for at least five years.</li>
            </ul>

            <div class="callout">
              <div class="callout-icon">i</div>
              <div>
                Many enforcement actions target <strong>missing paperwork</strong>, not just inappropriate use. A
                well-structured consent + rationale file is your first defence.
              </div>
            </div>

            <div class="section-label">Supply-chain & cold-chain</div>
            <h2>5. Supply-chain verification & cold-chain integrity</h2>
            <p>WHO highlights four high-risk clusters: counterfeit, incorrect potency, misuse and cold-chain breaks.</p>
            <ul>
              <li>Verify supplier licences, accreditations and COAs for each batch.</li>
              <li>Record batch/lot numbers across prescribing, dispensing and inventory.</li>
              <li>Maintain 24/7 temperature logs for storage and transport.</li>
              <li>Quarantine and document any deviation outside the approved range.</li>
              <li>Keep written procedures for destruction / return of suspect product.</li>
            </ul>

            <div class="checklist">
              <h3>Cold-chain log essentials</h3>
              <ul>
                <li>Batch ID and product description.</li>
                <li>Time-stamped temperature readings.</li>
                <li>Responsible staff initials.</li>
                <li>Deviation notes + action taken.</li>
              </ul>
            </div>

            <div class="section-label">Marketing & claims</div>
            <h2>6. GLP-1 marketing & claims compliance</h2>
            <p>WHO and national regulators consider GLP-1 promotional claims a core risk area. Avoid:</p>
            <ul>
              <li>Guaranteed outcomes (‚Äúlose X kg in Y weeks‚Äù).</li>
              <li>‚ÄúNo side effects‚Äù, ‚Äúrisk-free‚Äù or similar absolutes.</li>
              <li>Before/after photos without clear disclosure.</li>
              <li>Implied cures or disease reversal claims.</li>
            </ul>
            <p>Safer phrasing focuses on monitored therapy and potential support:</p>
            <ul>
              <li>‚Äúmay support medically supervised weight management‚Äù,</li>
              <li>‚Äúpart of a broader clinical programme‚Äù,</li>
              <li>‚Äútherapy monitored by licensed clinicians‚Äù.</li>
            </ul>

            <div class="section-label">Audits & response</div>
            <h2>7. Audit red flags & emergency response planning</h2>
            <p>Common triggers for regulatory or payer audits include:</p>
            <ul>
              <li>Rapid patient-count growth without matching documentation.</li>
              <li>High reliance on compounded products with limited COAs.</li>
              <li>Missing or inconsistent cold-chain logs.</li>
              <li>Non-standard sourcing or cross-border batches.</li>
              <li>Promotional claims that diverge from product labelling.</li>
            </ul>
            <p>When an audit notice arrives, your plan should:</p>
            <ul>
              <li>Freeze questionable batches immediately.</li>
              <li>Assemble eligibility, consent, COAs and temperature logs.</li>
              <li>Assign a single compliance lead as contact point.</li>
              <li>Respond within required time frames with complete documentation.</li>
              <li>Pause aggressive marketing until the review is closed.</li>
            </ul>

            <div class="section-label">Download</div>
            <h2>8. Download the full 2026 GLP-1 WHO Compliance Pack</h2>
            <p>
              To avoid building everything from scratch, the downloadable pack converts this framework into
              ready-to-use operational documents:
            </p>
            <ul>
              <li>GLP-1 eligibility checklist &amp; prescribing rationale template.</li>
              <li>Off-label documentation and informed-consent templates.</li>
              <li>Supply-chain &amp; cold-chain log sheets.</li>
              <li>Compounding partner verification forms &amp; COA trackers.</li>
              <li>Adverse-event reporting forms and escalation flow.</li>
              <li>Marketing-claims review checklist.</li>
              <li>Final one-page compliance checklist for internal audits.</li>
            </ul>

            <a class="btn-primary" href="https://branimirvrnoga.gumroad.com/l/WHOGLP-12026guidance" target="_blank" rel="noopener">
              üëâ Get the 2026 GLP-1 WHO Compliance Pack (PDF)
            </a>

            <div class="faq">
              <h2>9. Quick professional FAQ</h2>

              <div class="faq-item">
                <div class="faq-q">Is this pack legal advice?</div>
                <div class="faq-a">
                  No. It is an operational documentation framework aligned with the themes of the WHO advisory.
                  Final compliance decisions must be taken with your legal and regulatory team.
                </div>
              </div>

              <div class="faq-item">
                <div class="faq-q">Which markets can use this?</div>
                <div class="faq-a">
                  The structure is global, based on WHO risk language. Local law always prevails; adapt forms to your
                  jurisdiction and payer requirements.
                </div>
              </div>

              <div class="faq-item">
                <div class="faq-q">Does this replace existing SOPs?</div>
                <div class="faq-a">
                  No ‚Äì it is designed to bolt onto your existing SOP stack or help you rapidly build one where none
                  exists, with clear logs and templates for audits.
                </div>
              </div>

              <div class="faq-item">
                <div class="faq-q">Who inside an organisation should own this?</div>
                <div class="faq-a">
                  Typically a compliance lead, medical director or operations manager ‚Äì with clear responsibility for
                  maintaining logs, templates and periodic internal reviews.
                </div>
              </div>
            </div>
          </div>
        </article>

        <aside class="sidebar">
          <div class="sidebar-card">
            <div class="badge"><span>‚óè</span> COMPLIANCE TOOLKIT</div>
            <h3>GLP-1 Documentation Stack</h3>
            <p>
              Turn the WHO advisory into traceable eligibility, consent, supply-chain and adverse-event logs that can
              be shown in any payer or regulatory audit.
            </p>
            <div class="ad-slot small">
              Included in the pack: checklists, forms, logs and review sheets.
            </div>
          </div>

          <div class="sidebar-card">
            <h3>Who this pack is for</h3>
            <p>Built for organisations, not individual patients:</p>
            <ul class="link-list">
              <li>‚Ä¢ GLP-1 &amp; metabolic clinics</li>
              <li>‚Ä¢ Tele-health GLP-1 programs</li>
              <li>‚Ä¢ Pharmacies &amp; compounding labs</li>
              <li>‚Ä¢ Cross-border / online distributors</li>
            </ul>
          </div>

          <div class="sidebar-card">
            <h3>Related medical & compliance guides</h3>
            <ul class="link-list">
              <li><a href="/medical-bill-overcharge-charity-care/">Medical Bill Overcharge &amp; Charity Care ‚Äì Reduce hospital debt</a></li>
              <li><a href="/background-check-dispute/">Background Check Dispute ‚Äì Fix employment &amp; tenant reports</a></li>
              <li><a href="/us-credit-report-error-dispute/">U.S. Credit Report Error Dispute ‚Äì Full deletion guide</a></li>
            </ul>
          </div>

          <div class="sidebar-card">
            <div class="badge"><span>‚óè</span> ADS / AFFILIATE</div>
            <h3>Partner placements</h3>
            <p>Ideal for GLP-1 speciality insurers, regulatory platforms, audit software or lab partners.</p>
            <div class="ad-slot">
              Ad placeholder ‚Äì GLP-1 compliance / clinical software / audit tools.
            </div>
          </div>
        </aside>
      </main>

      <div class="ad-slot" style="margin-top:22px;">
        Second display slot ‚Äì for GLP-1 compliance services, legal partners or enterprise licences.
      </div>

      <footer>
        <div>¬© 2026 Skillona.ai ¬∑ Educational only. Not legal, regulatory or medical advice.</div>
        <div>
          <a href="/about.html">About</a> ¬∑
          <a href="/disclaimer.html">Disclaimer</a> ¬∑
          <a href="/contact.html">Contact</a>
        </div>
      </footer>

    </div>
  </div>

  <!-- Structured data: Article -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "Article",
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://skillona.ai/glp1-who-guidance-2026/"
    },
    "headline": "GLP-1 WHO 2026 Compliance Pack ‚Äì Clinics, Tele-Health, Pharmacies & Compounding Partners",
    "description": "Professional 2026 WHO GLP-1 compliance framework and documentation pack for clinics, tele-health platforms, pharmacies, compounding facilities and distributors.",
    "inLanguage": "en-US",
    "image": "https://skillona.ai/assets/og/glp1-who-guidance-2026.png",
    "author": {
      "@type": "Organization",
      "name": "Skillona.ai"
    },
    "publisher": {
      "@type": "Organization",
      "name": "Skillona.ai",
      "logo": {
        "@type": "ImageObject",
        "url": "https://skillona.ai/logo.png"
      }
    },
    "datePublished": "2026-01-01",
    "dateModified": "2026-01-01"
  }
  </script>
</body>
</html>
